Business Wire

VA-DXC-TECHNOLOGY

2.1.2020 10:02:09 CET | Business Wire | Press release

Share
New Shared Mobility Concept, Luxoft HALO, Introduces a Revolutionary Digital, Consumer-Grade In-Vehicle Experience

Luxoft , a DXC Technology Company (NYSE: DXC), today in collaboration with LG Electronics, Amazon and Mapbox unveiled Luxoft HALO, the company’s latest shared mobility concept featuring a revolutionary digital, consumer-grade in-vehicle experience. Luxoft HALO will be formally debuted at CES® 2020, Jan. 7-10, 2020, Las Vegas, NV.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200102005099/en/

At home, consumers expect their digital experiences to be simple, convenient and accessible at any time across a range of devices. Increasingly, consumers also expect access to their favorite content and services, in the vehicle and on the go.

Luxoft HALO shared mobility concept demonstrates how all consumers’ mobility needs can be seamlessly integrated with their personal digital lifestyle.

”Together with our key partners, we can now deliver a complete, highly personalized and intelligent in-vehicle consumer-grade experience, powered by webOS Auto, the platform for shared and intelligent mobility,” said Vildan Hasanbegovic, director of partnerships and head of marketing at Luxoft Automotive. ”It’s an open platform that delivers, with exceptional quality, an existing ecosystem of intelligent services and dynamic content — from in-vehicle infotainment to connected video streaming services and more — that is increasingly becoming an essential part of consumers‘ personal digital lifestyles.”

Luxoft can already deploy webOS Auto to large-scale series production systems, including:

  • Rear Seat Entertainment (RSE) for traditional needs;
  • Rear Seat Entertainment (RSE) with ride-hailing mode;
  • Cabin display for ride-hailing systems; and
  • Center stack display for ride-hailing systems.

Partner Innovations Showcased in Luxoft HALO

LG Electronics and webOS Auto

webOS Auto is an open and ideal platform for shared and intelligent mobility. webOS Auto provides features, and functionality, and incorporates all essential components such as multimedia processing, multi-display control, connectivity, security, offering improved comfort and convenience to passengers.

Alexa Auto

Alexa already helps you simplify and organize your life at home – now you can take her with you on the go with Alexa Auto. Alexa can help you play music, get directions, place calls, listen to audiobooks, control your smart home, and more, with just your voice – so you can keep your hands on the wheel and eyes on the road. Alexa is already available in dozens of vehicles from leading automakers, and Amazon has released services like the Alexa Auto SDK that make it easy for automakers and suppliers to integrate Alexa directly into their infotainment system. To learn more, visit amazon.com/alexa-auto/ .

Mapbox

Mapbox is a live location data platform powering maps and navigation experiences for mobile, web, gaming, and automotive. Mapbox maintains SDKs for developers building for webOS Auto, Android, iOS, Unity 3D, and web, and APIs for rendering maps and performing spatial functions. Every month, over 150,000 developers build with Mapbox. Over 45,000 mobile apps are powered by Mapbox SDKs. Applications and platforms built by developers using Mapbox reach more than 600 million monthly active users.

Luxoft at CES® 2020

Visit Luxoft at CES for a personal, hands-on experience of Luxoft HALO and to experience the future of shared and intelligent mobility; booth #6928, North Hall, Tech East, Las Vegas Convention and World Trade Center.

About Luxoft

Luxoft, a DXC Technology Company, (NYSE: DXC), is a digital strategy and software engineering firm providing bespoke technology solutions that drive business change for customers the world over. Luxoft uses technology to enable business transformation, enhance customer experiences, and boost operational efficiency through its strategy, consulting, and engineering services. Luxoft combines a unique blend of engineering excellence and deep industry expertise, specializing in automotive, financial services, travel and hospitality, healthcare, life sciences, media and telecommunications. For more information, please visit www.luxoft.com .

About DXC Technology

DXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. With decades of driving innovation, the world’s largest companies trust DXC to deploy our enterprise technology stack to deliver new levels of performance, competitiveness and customer experiences. Learn more about the DXC story and our focus on people, customers and operational execution at www.dxc.technology .

All information set out in the materials is provided in good faith but does not form part of or constitute an offer or contract. Statements, figures, plans, views and representations are for presentation purposes and indicative only. Luxoft has made reasonable efforts to include accurate information, wherever possible. However, Luxoft makes no warranties or representations, expressed or implied, as to the completeness of the information provided. Luxoft will not be liable for any damages, including but not limited to special or consequential damages, that result from the use of, or the inability to use, the material contained in these materials .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye